MDGL
Madrigal Pharmaceuticals Inc
Halal Rating :
Last Price
$302.04
Last updated:
Market Cap
-
7D Change
-0.55%
1 Year Change
29.53%
Company Overview
Industries
Exchange
Next Earnings Date
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of fatty liver disease. Their lead product candidate, resmetirom, is being developed for the treatment of NASH (non-alcoholic steatohepatitis), a serious liver condition that can lead to cirrhosis.
Use of Interest
Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
---|---|---|---|---|---|---|
Sept. 30, 2024 | $62.17m | $182.16m | - | $3.68m | 0.00% | 2.02% |
June 30, 2024 | $14.64m | $180.83m | - | $3.66m | 0.00% | 2.02% |
Company Impact
Help us evaluate Madrigal Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.